LATANOPROST - Generic Drug Details

What are the generic drug sources for latanoprost and what is the scope of patent protection?

Latanoprost is the generic ingredient in seven branded drugs marketed by Sun Pharm, Thea Pharma, Amring Pharms, Apotex Inc, Bausch And Lomb, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Mankind Pharma, Micro Labs, Pharmobedient, Sandoz, Somerset, Upjohn, and Alcon Labs Inc, and is included in eighteen NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost has fifty-three patent family members in thirty-one countries.

There are twenty drug master file entries for latanoprost. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LATANOPROST

International Patents:	53
US Patents:	21
Tradenames:	7
Applicants:	16
NDAs:	18
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	206
Drug Prices:	Drug price trends for LATANOPROST
Drug Sales Revenues:	Drug sales revenues for LATANOPROST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATANOPROST
What excipients (inactive ingredients) are in LATANOPROST?	LATANOPROST excipients list
DailyMed Link:	LATANOPROST at DailyMed

See drug prices for LATANOPROST

See drug sales revenues for LATANOPROST

Recent Clinical Trials for LATANOPROST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE4
Alcon Research	PHASE4
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,	PHASE4

See all LATANOPROST clinical trials

Generic filers with tentative approvals for LATANOPROST

Applicant	Application No.	Strength	Dosage Form
		0.005%	SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for LATANOPROST

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for LATANOPROST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	8,450,344		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,993,470		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,415,043			Y

Expired US Patents for LATANOPROST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	4,599,353
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	5,296,504
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	7,163,959

International Patents for LATANOPROST

Country	Patent Number	Title	Estimated Expiration
Canada	2702478	COMPOSITION OPHTALMOLOGIQUE (OPHTHALMIC COMPOSITION)
South Korea	20100087107
European Patent Office	2588078

Supplementary Protection Certificates for LATANOPROST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
0364417	SPC/GB97/014	United Kingdom		PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107

Market Dynamics and Financial Trajectory for Latanoprost

Last updated: February 12, 2026

What Is Latanoprost and How Is It Used?

Latanoprost is a prostaglandin analog approved primarily for reducing intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Marketed under various brand names like Xalatan, it gained FDA approval in 1996. The drug is delivered via eye drop.

What Are the Market Drivers for Latanoprost?

Rising Prevalence of Glaucoma

The global glaucoma market was valued at approximately $3.7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% through 2030. Factors include aging populations and increased screening efforts.

Aging Demographics

The World Health Organization reports that by 2050, people aged 60 and older will reach 2 billion worldwide. Age-related glaucoma incidence makes this demographic a key revenue source.

Advantages Over Alternatives

Latanoprost's once-daily dosing improves patient adherence compared to other medications (e.g., beta-blockers, which require multiple daily doses). Its favorable safety profile and efficacy contribute to sustained demand.

Patent and Generic Landscape

The original patent for Xalatan expired in 2019 in the U.S., leading to a proliferation of generics which significantly reduced costs and expanded access. Generic versions now capture over 70% of market share.

How Do Market Trends Affect Revenue Growth?

Penetration in Emerging Markets

Developing countries show increased penetration due to improved healthcare infrastructure and lower drug costs stemming from generics. The International Agency for Prevention of Blindness forecasts glaucoma management to expand rapidly in Asia, Africa, and Latin America.

Competitive Dynamics

The market includes branded drugs like Xalatan and generics; key competitors include tafluprost, bimatoprost, and travoprost, which have similar mechanisms. Competition influences pricing strategies and margins.

Reimbursement Policies

Health insurance coverage and government reimbursement schemes influence sales volume, especially in mature markets. In the U.S., Medicare and Medicaid policies support coverage for branded and generic prostaglandins.

What Are Future Revenue Projections?

Market Forecast (2023–2030)

Global glaucoma drug revenues are expected to increase from $3.7 billion in 2022 to around $5.8 billion by 2030, CAGR of 5.1%. Latanoprost remains the dominant topical agent, accounting for more than 50% of the prostaglandin segment.

Impact of Patent Expiry

Post-2019 generics have driven prices down, causing revenue shifts from branded to generic products. While total market growth remains positive, profit margins for original patents holders have declined by an estimated 30% since patent expiration.

Pipeline and Innovation

Research into sustained-release formulations, combination drugs, and new delivery methods (e.g., eye implants) could offset revenue losses from generics. Clinical trials for sustained-release implants are ongoing, with some candidates nearing regulatory review.

What Financial Risks and Opportunities Exist?

Cost Competition

Generic introduction has slashed prices by up to 50% in key markets, squeezing profit margins for branded versions.

Patent Litigation

Patent disputes may delay generic entry or lead to market exclusivity extensions. Companies that defend patents successfully can maintain higher prices longer.

Market Expansion

Growing acceptance in emerging markets, facilitated by lower-cost generics and improved healthcare access, presents long-term sales opportunities.

Regulatory Considerations

Stringent regulatory approval processes in developed markets could delay new formulations, but streamlined pathways in developing countries expand access and revenue.

How Do Competitive and Regulatory Factors Shape Financial Outlook?

Factor	Impact
Patent Expiry	Sharp decline in revenues for original brands (~2019)
Generic Competition	Reduced prices; increased volume
Innovation Pipeline	Potential revenue growth through new products
Regulatory Environment	Influences timing of market entry and approval

Summary of Financial Trajectory

• Pre-Patent Expiry (pre-2019): Dominance of branded Xalatan with high margins.
• Post-Patent Expiry (2019 onward): Decline in branded sales; escalation in generic market share and reduced prices.
• Long-term Outlook: Growth driven by emerging markets and pipeline innovations; revenue stability depends on formulation advancements and patent protection.

---

Key Takeaways

• Latanoprost's primary market driver remains glaucoma prevalence, especially in aging populations.
• Patent expiration in 2019 has prompted a shift toward generics, reducing profit margins for original manufacturers.
• Market expansion into emerging countries offers growth opportunities; regulatory and pricing pressures remain challenges.
• Innovation, including sustained-release formulations, could mitigate generic-driven revenue declines.
• Revenue growth from 2023 to 2030 is projected at approximately 5% CAGR, with upward potential from pipeline developments.

---

FAQs

Q1: How significantly did patent expiry impact Latanoprost revenues?
Patent expiry in 2019 led to a sharp decline in branded drug sales, with generic versions capturing over 70% of the market share. Revenue for original brands decreased by approximately 30–40% in the subsequent years.

Q2: What competitive strategies are companies pursuing for Latanoprost?
Manufacturers focus on cost reduction, developing novel formulations (e.g., sustained-release devices), and expanding into emerging markets. Patent litigation defending exclusivity also plays a role.

Q3: Are there upcoming alternatives to Latanoprost?
Yes. Some drugs under clinical development include combination therapies with lower dosing frequencies, new prostaglandin analogs with improved efficacy, and sustained-release implants.

Q4: How do regulatory policies influence Latanoprost's market?
Regulatory approvals affect the timing of drug entry into different markets. Stringent standards can delay launches; streamlined pathways, especially for generics, facilitate market penetration.

Q5: What is the outlook for Latanoprost in developing countries?
Growing healthcare access and the availability of affordable generics support expanding sales, though infrastructure and awareness remain barriers in some regions.

---

References

1. MarketResearch.com. "Glaucoma Drugs Market Analysis," 2022.
2. WHO. "World Report on Vision," 2019.
3. IQVIA. "Global Ophthalmic Drugs Market Report," 2022.
4. U.S. FDA. "Xalatan New Drug Application," 1996.
5. Statista. "Glaucoma Market Revenue Forecast," 2022.